---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-020125"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T15:14:44.255324+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines reports Q4 net loss $161.5M; cash $1.85B; pipeline on track for pivotal trials

## Summary
- Q4 2023 net loss $161.5M vs $56.5M YoY; full year net loss $436.4M vs $248.7M YoY.
- Revenue fell to $0.7M (Q4) and $11.6M (FY) due to Sanofi collaboration termination in 2023.
- Cash, equivalents and securities $1.85B as of Dec 31, 2023, up from $644.9M a year ago (EQRx acquisition and equity offering).
- Plans to start pivotal Phase 3 trials for RMC-6236 in 2L NSCLC and 2L PDAC in H2 2024.
- 2024 GAAP net loss guidance $480M-$520M; cash runway into 2027.

## SEC filing metadata
- accession: 0000950170-24-020125
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000095017024020125/0000950170-24-020125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000095017024020125/rvmd-20240226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-020125
- JSON: https://secwatch.observer/filing/0000950170-24-020125.json
- Plain text: https://secwatch.observer/filing/0000950170-24-020125.txt

## Key facts
- Earnings Releases
  Revolution Medicines, Inc. reported financial results for the quarter and year ended December 31, 2023.
  - Period: the quarter and year ended December 31, 2023
  - Result: reported results
  source text: Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000095017024020125/0000950170-24-020125-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.